PSNL — Personalis, Inc.

Summary of Personalis Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $17.3 million, a 3% increase year-over-year.
• Full Year 2025 Revenue: $69.6 million, reflecting a transitional phase with a nearly $20 million decline in revenue from Natera.
• Clinical Tests Delivered: 6,183 tests in Q4, a 41% sequential growth and 329% year-over-year increase.
• Biopharma Revenue: $10.9 million in Q4, down from $12.2 million in Q4 2024; full year biopharma revenue was $49 million, down from $51 million.
• Gross Margin: 11% in Q4 and 22.7% for the full year, with expectations of continued margin compression into 2026.
• Net Loss: $23.8 million in Q4 and $81.3 million for the full year, consistent with 2024.
• Cash Position: $240 million at the end of Q4, with expected cash usage of approximately $100 million in 2026.

2. Strategic Updates and Business Highlights

• MRD Strategy Validation: The company emphasized its successful MRD (Minimal Residual Disease) strategy, with strong uptake of the NeXT Personal test.
• Medicare Coverage: Achieved coverage for breast and lung cancer, enhancing legitimacy and market confidence.
• Clinical Growth: Projected Clinical test volumes to quadruple in 2026, with an annual volume guidance of 43,000 to 45,000 tests.
• Innovation: Launched a real-time variant tracker report for the NeXT Personal test, allowing for dynamic monitoring of cancer mutations.
• Partnership Expansion: Continued collaboration with Tempus to enhance market reach, particularly in colorectal cancer.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue between $78 million and $80 million, with Clinical revenue projected at $10 million to $11 million from newly covered tests.
• Biopharma Revenue Expectations: Anticipated growth to $20 million to $21 million, driven by MRD testing.
• Gross Margin Expectations: Forecasted to be between 15% and 20%, with the first quarter expected to be the lowest point of the year.
• Investment Strategy: Focus on scaling Clinical volumes and market share, with a commitment to high-margin growth in the future.

4. Bad News, Challenges, or Points of Concern

• Revenue Declines: Experienced a significant decline in revenue from legacy contracts, particularly from Natera, impacting overall revenue growth.
• Margin Compression: Intentional margin dilution expected as the company invests in scaling its Clinical business ahead of reimbursement revenue.
• Market Competition: Increased competition in the MRD space, with new entrants and consolidation among larger players, raising concerns about maintaining market share.
• Operational Risks: Potential variability in revenue due to the uneven biopharma spending environment and reliance on Medicare coverage decisions.

5. Notable Q&A Insights

• Reimbursement Impact: Medicare coverage has improved clinician receptivity and ordering patterns, enhancing the company's credibility in the market.
• Biopharma Stability: No significant pushouts or cancellations in biopharma contracts were reported, indicating a stable outlook despite previous challenges.
• Volume Expectations: The company expects Clinical volumes to increase significantly, with a focus on deepening relationships with existing oncologists while expanding its sales force.
• Future Reimbursement Submissions: Plans to pursue reimbursement for neoadjuvant breast and colorectal cancer, with ongoing evidence generation efforts to support these initiatives.
• Operational Efficiency: Continuous efforts to automate and streamline workflows are underway, aimed at improving margins as the business scales.

Overall, Personalis is positioned for growth in the MRD testing market, with a strong focus on innovation and strategic partnerships, despite facing challenges related to revenue transitions and competitive pressures.